Vaccination in Neurological Autoimmune Disorders

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".

Deadline for manuscript submissions: closed (20 July 2021) | Viewed by 313

Special Issue Editors

Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA
Interests: HIV/SIV/SHIV; neuroAIDS; transmission; drugs of abuse; HIV cure; gut homing molecules; immunotherapy; mucositis
Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
Interests: Neuroimmunology (including Multiple Sclerosis (MS) and related disorders); pediatric-onset MS
Dr. Gabrielle Macaron
Guest Editor
1. Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA
2. Faculté de médecine, Université Saint Joseph de Beyrouth, Department of Neurology, Hôtel Dieu de France Hospital, Beirut, Lebanon
Interests: neuroimmunology (including MS and related disorders; cognitive function in MS

Special Issue Information

Dear colleagues,

Vaccination has made an undeniable contribution in the prevention of numerous infectious diseases and associated morbidity and mortality, and represents a key pillar of an efficient healthcare system. The relationship between vaccination and autoimmune disease has been questioned for decades, after observing a relationship between Guillain Barré syndrome and the swine influenza vaccine in the 1970s.

Cases of vaccination-triggered autoimmune neurological diseases remain rare and poorly understood. On the other hand, autoimmune neurological diseases are often treated with immunosuppressive therapies. Whether vaccines are as effective with each treatment approach needs further clarification. Moreover, recommendation guidelines for vaccination schedules in such patients have been developed for some disorders but remain elusive.

The role of this Special Issue is to provide an updated review of current knowledge in the field of vaccination and neurological autoimmune disorders in an attempt to guide practice. We cordially invite you to participate in this Special Issue, based on your extensive knowledge and experience in the field.

Dr. Siddappa Byrareddy
Dr. Mary Rensel
Dr. Gabrielle Macaron
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • autoimmunity
  • disease modifying therapies
  • multiple sclerosis
  • neurological
  • vaccination
  • Guillain Barre
  • neuropathies

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop